曲妥珠单抗联合化疗治疗HER-2阳性乳腺癌女性患者的效果

Effect of trastuzumab combined with chemotherapy on breast cancer women with HER-2 positive

目的探索曲妥珠单抗联合化疗在治疗人表皮生长因子受体-2(HER-2)阳性乳腺癌中的临床效果。方法选取我院HER-2阳性乳腺癌患者73例,按住院时间分为两组。对照组36例采取曲妥珠单抗治疗,观察组37例采取曲妥珠单抗联合化疗治疗。比较两组肿瘤控制效果、肿瘤标志物、免疫指标、激素指标、细胞核相关抗原(Ki67)表达以及不良反应发生情况。结果两组疗效比较,P<0.05。干预后两组癌胚抗原(CEA)、细胞核相关抗原(Ki67)、糖类抗原125(CA-125)、CD_(8)^(+)、CD_(4)^(+)/CD_(8)^(+)水平均降低,且观察组低于对照组(P<0.05)。干预后两组CD_(3)^(+)、CD_(4)^(+)、雌激素受体(ER)、孕激素受体(PR)均升高,且观察组明显高于对照组(P<0.05)。两组不良反应比较,P>0.05。结论HER-2阳性乳腺癌采用曲妥珠单抗联合化疗治疗可降低肿瘤标志物水平,改善机体免疫指标,缓解Ki67、PR、ER水平,疗效确切且具有一定安全性。

Objective To explore the clinical effect of trastuzumab combination chemotherapy in the treatment of human epidermal growth factor receptor-2(HER-2)-positive breast cancer.Methods 73 cases of HER-2 positive breast cancer patients were selected and divided into two groups according to the admission time.36 cases in the control group were treated with trastuzumab and 37 cases in the observation group were treated with trastuzumab combined with chemotherapy.The tumor control effect,tumor markers,immune markers,hormone markers,nucleus-related antigen(Ki67)expression and the occurrence of adverse reactions were compared between the two groups.Results The comparison of efficacy between the two groups was with P<0.05.After intervention,the levels of carcinoembryonic antigen(CEA),nucleus-associated antigen(Ki67),sugar antigen 125(CA-125),CD_(8)^(+),CD_(4)^(+)/CD_(8)^(+)all decreased,and those in the observation group were lower than those in the control group(P<0.05).After intervention,the levels of CD_(3)^(+),CD_(4)^(+),estrogen receptor(ER)and progesterone receptor(PR)all increased in the two groups,and those in the observation group were higher than those in the control group(P<0.05).There was no significant difference in the incidence of adverse reaction between the two groups(P>0.05).Conclusion Trastuzumab combined with chemotherapy for HER-2 positive breast cancer can reduce the levels of tumor markers,improve the immune index,alleviate the levels of Ki67,PR and ER.